In December 2018, the Department of Health and Social Care [DHSC] published actions that the health and care system should take to prepare for a ‘no deal’ scenario including relating to the supply of human medicines.
This guidance has since been updated, and in June 2019 the DHSC provided a detailed overview of the Government’s multi layered approach to contingency planning which is aimed at preventing disruptions to the supply of medicine to patients in the event of a no-deal EU exit on 31 October.
The updated guidance confirmed that the DHSC continues to receive very good engagement from pharmaceutical manufacturers on developing their stock management plans for prescription only medicines and pharmacy medicines to ensure supply for patients is maintained across the NHS in case of delays at the border. DHSC has also secured contract agreements for additional warehouse space for stockpiled medicines, including ambient, refrigerated and controlled drug storage.
The Government also reiterated their guidance regarding stockpiling and the risks to availability of medicines if organisations other than manufacturers stockpile or if GPs or others prescribe or order more than they usually would.
As part of AAH Pharmaceuticals preparations we are following and continue to follow the advice from the DHSC regarding a multi-layered approach to Brexit contingency planning.